Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2011

01-09-2011 | Research

Divergent Squamous Differentiation in Upper Urothelial Carcinoma—Comparative Clinicopathological and Molecular Study

Authors: Ljubinka Jankovic Velickovic, Zana Dolicanin, Takanori Hattori, Ivana Pesic, Biljana Djordjevic, Mariola Stojanovic, Jablan Stankovic, Milan Visnic, Vladisav Stefanovic

Published in: Pathology & Oncology Research | Issue 3/2011

Login to get access

Abstract

Upper urothelial carcinoma (UUC) has a plasticity to demonstrate divergent differentiation with squamous metaplastic elements. There was no previous study exploring profiling of molecular markers in metaplastic squamous upper urothelial carcinoma (SUUC) and conventional upper urothelial carcinoma (CUUC). The aims of this study was to compare expression of the phenotypic characteristics of tumors and molecular markers (p53, p16, cyclin D1, E-cadherin, HER-2, Ki-67, Bcl-2, Bax) in SUUC and CUUC. SUUC was detected in 20% of 44 patients. There was significant difference between SUUC and CUUC in the pathological stage, grade, growth and presence of lymphovasular invasion (p < 0.05; 0.05; 0.05; 0.01 respectively). The mean Ki-67 and p53 labeling index was significantly higher in SUUC than in CUUC (p < 0.05; 0.05). There was no significant difference in the expression of p16, cyclin D1, E-cadherin, HER-2, Bcl-2 and Bax between SUUC and CUUC. Univariant model showed that SUUC was significantly associated with lymphovascular invasion (p = 0.007), Ki-67 activity (p = 0.016) and growth (p = 0.026). Exploration of UUC with squamous divergent differentiation showed changes in phenotypic characteristics and Ki-67, as well as similar molecular profile with CUUC.
Literature
1.
Shanks JH, Iczkowski KA (2009) Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology 54:885–900PubMedCrossRef
2.
Nigwekar P, Amin BM (2008) The many faces of urothelial carcinoma. An update with an emphasis on recently described variants. Adv Anat Pathol 15:218–233PubMedCrossRef
3.
Sung TM, Wang M, MacLennan TG, Eble NJ, Tan P-H, Lopez-Beltran A, Montironi R, Harris JJ, Kuhar M, Cheng L (2007) Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol 211:420–430PubMedCrossRef
4.
Amstrong BA, Wang M, Eble NJ, MacLennan TG, Montironi R, Tan P-H, Lopez-Beltran A, Zhang S, Baldridge AL, Spartz H, Cheng L (2009) TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Path 22:113–118CrossRef
5.
Martin EJ, Jenkins JB, Zuk JR, Blandy PJ, Baithun IS (1989) Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol 42:250–253PubMedCrossRef
6.
Perez-Montiel D, Wakely EP, Hes O, Michal M, Suster S (2006) High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Path 19:494–503CrossRef
7.
Young HR, Zukerberg R (1991) Microcystic transitional cell carcinoma of the urinary bladder. Am J Clin Pathol 96:635–639PubMed
8.
Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Drager BJ, Helpap B, Ayala AG, Tamboli P, Knowles MA, Sidransky D, Cordon-Cardo C, Jones PA, Cairns P, Simon R, Amin MB, Tyezinski JE (2004) Tumors of the urinary system. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) World Health Organization classification of tumours. Pathology and genetics. Tumours of the urinary system and male genital organs. IARC, Lyon, pp 93–109
9.
Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
10.
Genega EM, Kapali M, Torres-Quinones M, Huang WC, Knauss JS, Wang LP, Raghunath PN, Kozlowski C, Malkowicz SB, Tomaszewski JE (2005) Impact of the 1998 World health organization/international society of urological pathology classification system for urothelial neoplasms of the kidney. Mod Pathol 18:11–18PubMedCrossRef
11.
Benedict FW, Lerner PS, Zhou J, Shen X, Tokunaga H, Czerniak B (1999) Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18:1197–1203PubMedCrossRef
12.
Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP (2004) P53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22:1014–1024PubMedCrossRef
13.
Genega ME, Porter RC (2002) Urothelial neoplasms of the kidney and ureter. Am J Clin Pathol 117:S36–S48PubMedCrossRef
14.
Jung I, Messing E (2000) Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 7:325–334PubMed
15.
Amin BM (2009) Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Histological variants of urothelial carcinoma. Mod Path 22:S96–S118CrossRef
16.
Black CP, Brown AG, Dinney PC (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27:3–7PubMedCrossRef
17.
Lopez-Beltran A, Sauter G, Gasser T et al (1988) Squamous and glandular differentiation in urothelial bladder carcinomas. Histopathology, histochemistry and immunohistochemical expression of carcinoembryonic anrigen. Histol Histopathol 3:63–68PubMed
18.
Lopez-Beltran A, Requena JM, Alvarez-Kindelan J, Quintero A, Blanca A, Montironi R (2007) Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J Clin Pathol 60:332–335PubMedCrossRef
19.
Kamijima S, Tobe T, Suyama T, Ueda T, Igarashi T, Ichikawa T, Ito H (2005) The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 12:941–947PubMedCrossRef
20.
Fromont G, Roupret M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O (2005) Tissue microarray analysis of the prognostic value of E-cadherin, Ki-67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 48:764–770PubMedCrossRef
21.
El-kott AF (2007) Flow cytometry and Ki-67 expression in rat’s urinary bladder carcinogenesis treated with Allium Sativum. Cancer Ther 5:185–192
22.
Eltz S, Comperat E, Cussenot O, Rouprêt M (2008) Molecular and histological markers in urothelial carcinoma of the upper urinary tract. BJUI 102:532–535CrossRef
23.
Kunju LP, Lee CT, Montie J, Shah RB (2005) Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int 55:248–254PubMedCrossRef
24.
Shamsdin SA, Mehrabani D, Hosseinzadeh M (2008) Expression of Ki-67, C-erbB2 and EGFR in TCC of the urinary bladder and their correlation with tumor grading. Iranian Red Crescent Med J 10:95–99
25.
Aaltonen V, Koivunen J, Laato M, Peltonen J (2006) Heterogeneity of cellular proliferation within transitional cell carcinoma: correlation of protein kinase C alpha/betal expression and activity. J Histochem Cytochem 54:795–806PubMedCrossRef
26.
Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzales-Campora R, Requena MJ, Montironi R, Lopez-Beltran A (2006) Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 59:83–88PubMedCrossRef
27.
Xue-Ru Wu (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713–725CrossRef
Metadata
Title
Divergent Squamous Differentiation in Upper Urothelial Carcinoma—Comparative Clinicopathological and Molecular Study
Authors
Ljubinka Jankovic Velickovic
Zana Dolicanin
Takanori Hattori
Ivana Pesic
Biljana Djordjevic
Mariola Stojanovic
Jablan Stankovic
Milan Visnic
Vladisav Stefanovic
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9343-x

Other articles of this Issue 3/2011

Pathology & Oncology Research 3/2011 Go to the issue

Research

Association of mtDNA D-Loop Polymorphisms with Risk of Gastric Cancer in Chinese Population

Research

Expression and Amplification of Topoisomerase-2α in Type 1 and Type 2 Papillary Renal Cell Carcinomas and Its Correlation with HER2/neu Amplification

Research

Differential Biomarker Expression in Head and Neck Cancer Correlates with Anatomical Localization

Case Report

Cardiac Metastasis: A Rare Involvement of Primitive Neuroectodermal Tumour of the Lung

Research

Immunohistochemical Profile of Urothelial and Small Cell Carcinomas of the Bladder

Research

Downregulated Expression of Inhibitor of Growth 4 (ING4) in Advanced Colorectal Cancers: A Non-Randomized Experimental Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits